Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

287.35 +3.08 (+1.08%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Deep Dive Into United Therapeutics Stock: Analyst Perspectives (9 Ratings)
Via Benzinga
Disney To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
United Therapeutics and Intermountain Health Announce the First Patient Treated With External Liver Support Using a Bioengineered Liver
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation Concludes Enrollment of the ADVANCE OUTCOMES Study of Ralinepag for the Treatment of Pulmonary Arterial Hypertension
From United Therapeutics Corporation
Via Business Wire
Forecasting The Future: 7 Analyst Projections For United Therapeutics
Via Benzinga
Earnings Scheduled For April 30, 2025
Via Benzinga
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) - A Strong Candidate for GARP Investors
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) offers growth at a reasonable price, with strong profitability, no debt, and a PEG ratio of 0.68. A solid pick for long-term investors. 
Via Chartmill
AppLovin, Chewy And Carvana Are Among Top 11 Large Cap Losers Last Week (June 9-13): Are The Others In Your Portfolio?
11 large-cap stocks were worst performers last week: SJM, CHWY, IOT, UTHR, CVNA, APP, UAL, GRAB, EIX, LULU, MBLY. Analysts lower price forecasts. 
Via Benzinga
1 of Wall Street’s Favorite Stock with Exciting Potential and 2 to Keep Off Your Radar
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) – A Biotech Stock With Strong Fundamentals and Attractive Valuation
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) offers strong profitability, zero debt, and an undervalued stock price, making it a candidate for value investors in the biotech sector. 
Via Chartmill
Dow Gains 50 Points; US Small Business Optimism Index Rises In May
Via Benzinga
Topics Stocks
Insmed Catapults Into Breakout Territory On A 'Home Run' For Its Rival To United, Liquidia
Shares look likely to break out at the open after the biotech company unveiled promising results for a pulmonary arterial hypertension treatment. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Q1 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Biogen... 
Via StockStory
Topics Artificial Intelligence
Liquidia Scores FDA Nod For Lung Disease Drug Yutrepia, Faces Legal Challenge
Liquidia gains FDA approval for Yutrepia to treat PAH and PH-ILD, with funding in place despite ongoing patent litigation with United Therapeutics 
Via Benzinga
Topics Intellectual Property
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) - A Strong Candidate for GARP Investors
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) offers strong growth, profitability, and a cheap valuation, making it a standout for GARP investors following Peter Lynch's strategy. 
Via Chartmill
Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Myriad Genetics (NASDAQ:MYGN) and its peers. 
Via StockStory
Topics Artificial Intelligence
1 Safe-and-Steady Stock on Our Buy List and 2 to Ignore
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including United Therapeutics (NASDAQ:UTHR) and its peers. 
Via StockStory
Topics Artificial Intelligence
UTHR Q1 Earnings Call: Double-Digit Growth Continues, Pipeline Expansion Remains Central
Biotechnology company United Therapeutics (NASDAQ:UTHR) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 17.2% year on year to $794.4 million. Its non-GAAP profit... 
Via StockStory
Examining the Quality Attributes of UNITED THERAPEUTICS CORP (NASDAQ:UTHR).
A fundamental analysis of (NASDAQ:UTHR): Why UNITED THERAPEUTICS CORP (NASDAQ:UTHR) qualifies as a quality stock. 
Via Chartmill
3 Big Reasons to Love United Therapeutics (UTHR)
What a brutal six months it’s been for United Therapeutics. The stock has dropped 23.1% and now trades at $308, rattling many shareholders. This might have investors contemplating their next move. 
Via StockStory
Unpacking Q1 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Vertex... 
Via StockStory
Topics Artificial Intelligence
Following Peter Lynch’s approach: Does UNITED THERAPEUTICS CORP (NASDAQ:UTHR) fit the bill?
Let’s dive into UNITED THERAPEUTICS CORP (NASDAQ:UTHR) using Peter Lynch’s key investing principles, from earnings growth and debt levels to long-term scalability and valuation. 
Via Chartmill
The Top 3 Stock Picks at the World’s Greatest Hedge Fund
See which three stocks the world's most successful hedge fund, which generated returns of +30% for decades, had the biggest stakes in at the end of 2024. 
Via MarketBeat
Topics Regulatory Compliance
UNITED THERAPEUTICS CORP (NASDAQ:UTHR): A Potential Undervalued Opportunity
UNITED THERAPEUTICS CORP (NASDAQ:UTHR): A Potential Undervalued Opportunity 
Via Chartmill
1 Value Stock Worth Investigating and 2 to Brush Off
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few... 
Via StockStory
United Therapeutics (NASDAQ:UTHR) Reports Bullish Q1
Biotechnology company United Therapeutics (NASDAQ:UTHR) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 17.2% year on year to $794.4 million. Its GAAP profit of... 
Via StockStory
United Therapeutics Corporation Reports First Quarter 2025 Financial Results
From United Therapeutics Corporation
Via Business Wire
United Therapeutics (UTHR) To Report Earnings Tomorrow: Here Is What To Expect
Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow morning. Here’s what to look for. 
Via StockStory
Topics Government World Trade
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.